Nitrome Biosciences was awarded MBC BioLabs Celgene's Golden Ticket. This program is provided to promising, qualified entrepreneurs and offers priority admission or renewal, including rent support, for one year’s use of an MBC BioLabs bench and the MBC Fast-track core facilities. This unique offering provides state-of-the-art equipment and the runway to test hypotheses, gather data, and make important connections with the scientific and development community. Participants in this program may also have the opportunity to work with and receive mentorship from the Celgene team on drug discovery and development.  

Nitrome Biosciences is a member of Johnson & Johnson Innovations, LLC . Johnson & Johnson Innovations focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses.

Nitrome Biosciences  was awarded Audience Choice Award: 
This award is given to the company who “wows” the audience with their presentation.  

Nitrome Biosciences is a member of MBC Biolabs. MBC Biolabs: Shortening the path between the smallest and biggest companies is integral to the success of our model. Startups need insight into the most compelling applications for their technology as well as the data required to attract partnerships. 

Nitrome Biosciences competed against more than 40 other early stage biotech companies and won the Abbvie Golden Ticket. The Golden Ticket offers a priority admission, including rent support, for one year’s use of an MBC BioLabs bench and the MBC Fast-track core facilities. This unique offering provides state-of-the-art equipment and the runway to test hypotheses, gather data, and make important connections with the scientific and development community;  

Nitrome Biosciences Halting Parkinson's Disease

halting Parkinson's Disease

 

Our Approach 

In the News & Awards

Nitrome Biosciences is developing drugs against a new class of enzymes, initially targeting Parkinson’s disease. When successful, we will have found and characterized a new class of enzymes and will have a proprietary development path for disease-modifying drugs for multiple aging-dependent diseases. We are starting with Parkinson’s disease but this may be extended to include other neurodegenerative diseases, heart disease and cancer.